Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hormone sensitivity study related to catamenial epilepsy
ACTRN12624000803594Phase 4Not yet recruiting
- Sponsor
- The University of Auckland
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of estradiol, progesterone and avatrombopag in catamenial epilepsy (CE) (3 cohorts), sponsored by The University of Auckland. Primary endpoints: Electroencephalography endpoint 1 and Electroencephalography endpoint 2. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
estradiolprogesteroneavatrombopag
03
Conditions
catamenial epilepsy (CE)
Beyond the preview
Go deeper on ACTRN12624000803594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000803594.